Abstract
The pharmacology of Oxaprozin, a new nonsteroidal antiinflammatory drug (NSAID) of the propionic acid class, is summarized. In several animal models. Oxaprozin is either equipotent with or more potent than aspirin as an antiinflammatory and analgesic agent. It also has antipyretic, uricosuric, and immunologic properties. The principal antiinflammatory mechanism of action of Oxaprozin appears to be prostaglandin biosynthesis inhibition. Along with other NSAIDs. Oxaprozin has demonstrated some gastrointestinal side effects, but these appear to be less severe in the stomach than those of other drugs of this type. Oxaprozin does not cause intestinal tract lesions in rats, an advantage it shares with aspirin and sulindac only. In addition, although Oxaprozin has a short half-life in rats, it has a long plasma half-life in rhesus monkeys and in humans, and in fact has a longer half-life than any other NSAID currently in therapeutic use. Thus, Oxaprozin appears to be an effective, relatively safe, and long-acting antiinflammatory agent.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
